Show simple item record

dc.rights.licenseCC-BY-NC-ND
dc.contributorTammo Brunekreef
dc.contributor.advisorExterne beoordelaar - External assesor,
dc.contributor.authorHeuvel, Hélène van den
dc.date.accessioned2022-06-21T00:00:33Z
dc.date.available2022-06-21T00:00:33Z
dc.date.issued2022
dc.identifier.urihttps://studenttheses.uu.nl/handle/20.500.12932/41659
dc.description.abstractImmune mediated inflammatory diseases (IMIDs) are inflammatory conditions that are currently incurable. The treatment options currently used include corticosteroids, immunosuppressants, and biologicals. As IMIDs can cause significant tissue damage when untreated, early diagnosis is essential. This proves to be a challenge, as clinical manifestations vary largely between patients. One of the potential diagnostic tools could be antinuclear antibodies (ANAs). This is a group of various autoantibodies that target nuclear molecules. Some of these ANAs are exclusively associated with particular IMIDs. In addition, previous literature has demonstrated ANAs are present years prior to clinical diagnosis of the IMID. In light of these findings, the current thesis aims to explore the predictive value of positive ANA screening tests and specific ANA tests for development of IMIDs within six years following a positive ANA screening test or specific ANA test. In order to achieve the aim, the electronic health records of 1030 patients were analyzed to find new IMID diagnoses using a text mining algorithm. These patients were retrieved from a study conducted in 2014 (Otten et al.). In their study, the researchers aimed to evaluate the current strategy concerning ANA tests for the purpose of confirming IMID diagnoses. Based on their data, the predictive value of the ANA test results for future IMID development was explored. The findings of the current study demonstrate only a small proportion of the patients that were considered to be at high risk of future IMID development actually developed an IMID in the six years following the initial ANA tests. Nevertheless, the patients that developed an IMID in the years after the ANA tests were conducted were more likely to have positive ANA screening tests and positive specific ANA tests compared to patients with similar pretest probability for IMID development that did not develop an IMID. Hence, the findings suggest ANA tests could be used as predictors for IMID development in the near future. Especially in patients that have a high pretest probability of developing a future IMID based on clinical guidance, positive ANA test results could serve as a diagnostic tool.
dc.description.sponsorshipUtrecht University
dc.language.isoEN
dc.subjectIn this thesis the value of ANA screening tests and specific ANA tests for future development of immune mediated inflammatory diseases (IMIDs) was explored. Some ANAs are exclusively associated with particular IMIDs and have been demonstrated to be present in the years prior to clinical onset of particular IMIDs. The aim of this project was therefore to evaluate the predictive value of ANA tests for the development of IMIDs over the course of six years.
dc.titlePrediction of development of immune mediated inflammatory diseases with antinuclear antibodies
dc.type.contentMaster Thesis
dc.rights.accessrightsOpen Access
dc.subject.courseuuInfection and Immunity
dc.thesis.id4549


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record